Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

Landmark investments, portfolio progress, and expanded presence positionNovo Holdings for long-term growth and impact in Asia SINGAPORE, June 18, 2025 ...

In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

'Ozempic Penis' is the new side-effect that people have been turning their heads at, and users are reporting experiencing ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity ...

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, ...

Indian pharmaceutical companies are gearing up to launch cost-effective versions of the weight-loss and diabetes drug, semaglutide, post patent expiry in 2026.